MeSH term
Frequency | Condition_Probility | Adolescent | 5 | 0.0 |
Chronic Disease | 23 | 1.0 |
Female | 19 | 0.0 |
Humans | 30 | 0.0 |
Male | 18 | 0.0 |
Adult | 16 | 0.0 |
Age of Onset | 2 | 0.0 |
Cohort Studies | 5 | 0.0 |
Gene Frequency | 2 | 0.0 |
Heterozygote | 4 | 0.0 |
Homozygote | 2 | 0.0 |
*Point Mutation | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 19 | 0.0 |
Trypsin Inhibitor, Kazal Pancreatic/*genetics | 15 | 78.0 |
Aged | 5 | 0.0 |
Base Sequence | 3 | 0.0 |
DNA Mutational Analysis | 6 | 0.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Genotype | 5 | 0.0 |
Middle Aged | 10 | 0.0 |
Molecular Sequence Data | 4 | 0.0 |
*Mutation | 9 | 0.0 |
Pancreatitis, Alcoholic/genetics | 2 | 100.0 |
Phenotype | 3 | 0.0 |
*Trypsin | 9 | 33.0 |
Trypsinogen/genetics | 4 | 44.0 |
DNA Mutational Analysis/methods | 2 | 0.0 |
Pancreatitis/*genetics | 13 | 37.0 |
Prognosis | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 6 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Child | 7 | 0.0 |
Comparative Study | 4 | 0.0 |
Mutation | 7 | 0.0 |
Pancreatitis/diagnosis/*genetics | 3 | 50.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
*Genetic Predisposition to Disease | 4 | 0.0 |
Pedigree | 8 | 0.0 |
Trypsinogen/*genetics | 5 | 35.0 |
Cystic Fibrosis/genetics | 2 | 6.0 |
Genetic Screening | 4 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Trypsin Inhibitor, Kazal Pancreatic/genetics | 2 | 66.0 |
Mutation/genetics | 2 | 0.0 |
Exons/genetics | 2 | 0.0 |
Mutation/*genetics | 5 | 0.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/genetics | 3 | 4.0 |
Risk Factors | 3 | 0.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/*genetics | 4 | 2.0 |
Pancreatitis/genetics | 2 | 28.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Serine Proteinase Inhibitors/genetics | 2 | 22.0 |
Trypsin Inhibitor, Kazal Pancreatic/*genetics/metabolism | 2 | 66.0 |
India | 2 | 0.0 |
